Treatment of such diseases in adults as: – cryptococcal meningitis; the coccidioidomycosis; – invasive candidiasis; – candidiasis of the mucous membranes, including oropharyngeal candidiasis and esophageal candidiasis, candiduria, chronic candidiasis of the skin and mucous membranes; – chronic atrophic candidiasis (candidiasis caused by the use of dentures) with the inefficiency of local dental hygiene products; – vaginal candidiasis, acute or recurrent, when local therapy is not appropriate; – Candida balanitis when local therapy is not appropriate; – dermatomycosis, including mycosis of the feet, mycosis of smooth skin, inguinal dermatomycosis, multi-colored lichen and Candida infections of the skin, when indicated to use systemic therapy; – dermatophytic onychomycosis, when the use of other drugs is not advisable.
Fluconazol №1 Composition
active substance: fluconazole;
1 capsule contains 150 mg of fluconazole;
excipients: lactose monohydrate, potato starch; povidone, calcium stearate capsule shell contains titanium dioxide (E 171), gelatin, black ink (in the case of applying the company’s trademark – ZT; contain Glaze shellac 45% solution in ethanol, black iron oxide (E172), propylene glycol, concentrated ammonia solution) …
Fluconazol №1 Dosage form
The capsules are hard.
Basic physical and chemical properties: white hard gelatin capsules. The contents of the capsules are powder, white with a yellowish sheen. The presence of agglomerates of powder particles is allowed. It is allowed to apply the trademark of the enterprise – ZT on the capsule.
Fluconazol №1 Pharmacotherapeutic group
Antifungal agents for systemic use. Triazole derivatives. ATX code J02A C01.
Mechanism of action. Fluconazole is an antifungal agent of the triazole class. The primary mechanism of its action is the suppression of fungal 14-alpha-lanosterol demethylation, mediated by cytochrome P450 (CYP), which is an integral step in the biosynthesis of fungal ergosterol. The accumulation of 14-alpha-methyl-sterols correlates with the subsequent loss of ergosterol by the membrane of the fungal cell and may be responsible for the antifungal activity of fluconazole. Fluconazole is more selective for fungal cytochrome P450 enzymes than for various mammalian cytochrome P450 enzyme systems.
Treatment of such fungal infections in adults as (see section “Pharmacological”):
cryptococcal meningitis (see section “Peculiarities of use”);
coccidioidomycosis (see section “Peculiarities of use”);
candidiasis of the mucous membranes, including candidiasis of the oropharynx and candidiasis of the esophagus, candiduria, chronic candidiasis of the skin and mucous membranes;
chronic atrophic candidiasis (candidiasis caused by the use of dentures) with ineffective oral hygiene or local therapy;
vaginal candidiasis, acute or recurrent when local therapy is inappropriate;
candidal balanitis when topical therapy is inappropriate;
dermatomycosis, including mycosis of the feet, mycosis of smooth skin, inguinal dermatomycosis; tinea versicolor and candidal skin infections when systemic therapy is appropriate;
dermatophytic onychomycosis, when the use of other drugs is inappropriate.
Prevention of such diseases in adults:
Hypersensitivity to any component of the drug / other azole compounds. Concomitant use of fluconazole and terfenadine in patients who use fluconazole multiple times at doses of 400 mg / day or more. Concomitant use of fluconazole and other drugs that prolong the QT interval and are metabolized by the CYP3A4 enzyme (for example, cisapride, astemizole, pimozide, quinidine and erythromycin).